Table 1.
Summary of Specimens Sequenced in Analytical Validation Study for the NCI-MATCH NGS Assay
| Institution | Sensitivity, % | Specificity, % | Reproducibility, % | Limit of detection, % |
|---|---|---|---|---|
| FNLCR | 56 | 20 | 64 | 10 |
| MDACC | 45 | 20 | 64 | 10 |
| MGH | 58 | 20 | 64 | 10 |
| YSM | 56 | 20 | 64 | 10 |
| Total | 215 | 80 | 256 | 40 |
| Total unique specimens∗ | 198 | 5 | 16 | 3 |
| Total unique clinical specimens | 186 | 0 | 16 | 1 |
| Total unique cell lines | 12 | 5 | 0 | 2 |
FNLCR, Frederick National Laboratory for Cancer Research; MDACC, MD Anderson Cancer Center; MGH, Massachusetts General Hospital; YSM, Yale University School of Medicine.
∗
Some clinical specimens are used more than once because of scarcity of the variant type. Please refer to Supplemental Table S1 for complete details of all specimens sequenced.